Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection.
Stockholm, Sweden – February 12, 2024 – Biosergen AB (“Biosergen” or the “Company is pleased to announce that it has received permission to test BSG005 as rescue therapy in patients with invasive fungal infections.The Company’s partner, Alkem Laboratories Limited (“Alkem”), has received an approval of the Clinical Trial Application from the Central Drugs Standard Control Organization (CDSCO) in India. The approval allows for the initiation of the first patient study for BSG005 in a clinical trial designed to address unmet medical needs in invasive fungal infections. Biosergen and Alkem will